top of page
YAYINLAR:

1. Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism.

Wiersinga W, Žarković M, Bartalena L, Donati S, Perros P, Okosieme O, Morris D, Fichter N, Lareida J, von Arx G, Daumerie C, Burlacu MC, Kahaly G, Pitz S, Beleslin B, Ćirić J, Ayvaz G, Konuk O, Törüner FB, Salvi M, Covelli D, Curro N, Hegedüs L, Brix T; EUGOGO (European Group on Graves’ Orbitopathy). Eur J Endocrinol. 2018 Jun;178(6):635-643. doi: 10.1530/EJE-18-0039. Epub 2018 Apr 12.

 

2. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Kahaly GJ1, Riedl M2, König J3, Pitz S4, Ponto K4, Diana T2, Kampmann E2, Kolbe E2, Eckstein A5, Moeller LC6, Führer D6, Salvi M7, Curro N8, Campi I7, Covelli D7, Leo M9, Marinò M9, Menconi F9, Marcocci C9, Bartalena L10, Perros P11, Wiersinga WM12; European Group on Graves' Orbitopathy (EUGOGO).

Collaborators (23) Ayvaz GBaldeschi LBoborides KBoschi ABrix THClarke LDayan CDaumerie CDickinson AJFichter NHegedüs LKonuk OKrassas GELane CLazarus JMorris DSMourits MNardi MNeoh COrgiazzi JPearce SHSvon Arx GZarkovic M. Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-8587(18)30020-2. Epub 2018 Jan 31.

 

3. Graves’ orbitopathy as a rare disease in Europe: A European Group on Graves’ Orbitopathy (EUGOGO) position statement P. Perros, L. Hegedüs , L. Bartalena, C. Marcocci, G. J. Kahaly, L. Baldeschi, M. Salvi, J. H. Lazarus, A. Eckstein, S. Pitz, K. Boboridis, P. Anagnostis, G. Ayvaz, A. Boschi, T. H. Brix, N. Currò, O. Konuk, M. Marinò, A. L. Mitchell, B. Stankovic, F. B. Törüner, G. von Arx, M. Zarković  and W. M. Wiersinga.                                                                             Orphanet Journal of Rare Diseases (2017) 12:72

4. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP,

Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen

SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B,

Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial

Investigators. N Engl J Med. 2016 Jul 28;375(4):311-22. doi:

10.1056/NEJMoa1603827. Epub 2016 Jun 13

5. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines

for the Management of Graves' Orbitopathy. Bartalena L, Baldeschi L, Boboridis K, Eckstein A,

Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM; European Group on Graves'

Orbitopathy (EUGOGO).

Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828.Epub 2016 Mar 2.

6. The effect of thyroid autoimmunity on T-cell responses in early pregnancy. Turhan Iyidir O,

Konca Degertekin C, Sonmez C, Atak Yucel A, Erdem M, Akturk M, Ayvaz G.

J Reprod Immunol. 2015 Aug;110:61-6. doi: 10.1016/j.jri.2015.04.002. Epub 2015 May 8.

7. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European

Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Perros

P, Žarković M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi A, Bournaud C, Brix TH,

Covelli D, Ćirić S, Daumerie C, Eckstein A, Fichter N, Führer D, Hegedüs L, Kahaly GJ, Konuk O,

Lareida J, Lazarus J, Leo M, Mathiopoulou L, Menconi F, Morris D, Okosieme O, Orgiazzi J, Pitz

S, Salvi M, Vardanian-Vartin C, Wiersinga W, Bernard M, Clarke L, Currò N, Dayan C,

Dickinson J, Knežević M, Lane C, Marcocci C, Marinò M, Möller L, Nardi M, Neoh C, Pearce S,

von Arx G, Törüner FB.

Br J Ophthalmol. 2015 Nov;99(11):1531-5. doi: 10.1136/bjophthalmol-2015- 306733. Epub

2015 May 7.

8. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2

diabetes in Turkey-- GALATA study. Ayvaz G, Keskin L, Akin F, Dokmetas HS, Tasan E, Ar IB,

Uren E; GALATA Study Group.

Curr Med Res Opin. 2015 Apr;31(4):623-32. doi: 10.1185/03007995.2015.1019609. Epub

2015 Mar 16.

9. Serum levels of fetuin A are increased in women with gestational diabetes mellitus. Iyidir OT,

Degertekin CK, Yilmaz BA, Altinova AE, Toruner FB, Bozkurt N, Ayvaz G, Akturk M.

Arch Gynecol Obstet. 2015 Apr;291(4):933-7. doi: 10.1007/s00404-014- 3490-3. Epub 2014

Sep 27.

10. The effect of continuous subcutaneous insulin infusion therapy on acute

complications and pregnancy outcome in pregnant women with type 1

diabetes mellitus

Nuri Cakir, Isilay Kalan, Alev Altinova, Cigdem Ozkan, Mujde Akturk, Ceyla

Konca Degertekin, Ethem Turgay Cerit, Mehmet Muhittin Yalcin, Fusun Balos

Toruner, Ayhan Karakoc, Ilhan Yetkin & Goksun Ayvaz

Endocrine Abstracts (2014) 35 P492 DOI:10.1530/endoabs.35.P492

11. A lepromatous lepra case presented like diabetic foot

Mehmet Muhittin Yalcin, Tugce Emiroglu, Cigdem Ozkan, Alev Altinova, İlhan

Yetkin, Ayhan Karakoc, Goksun Ayvaz and Metin Arslan. Endocrine Abstracts

(2014) 35 P446 DOI:10.1530/endoabs.35.P446

12. The effect of calpain-10 gene polymorphism on the development of type 2 diabetes mellitus

in a Turkish population. Arslan E, Acik L, Gunaltili G, Ayvaz G, Altinova AE, Arslan M.

Endokrynol Pol. 2014;65(2):90-5. doi: 10.5603/EP.2014.0013.

13. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish

adults. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A,

Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J; TURDEP-II Study Group.

Eur J Epidemiol. 2013 Feb;28(2):169-80. doi: 10.1007/s10654-013- 9771-5. Epub 2013 Feb 14.

14. Irrational drug use in neuropathic pain treatment: a two year data analysis

E Tan, A Akıncı, G Ayvaz, T Erbaş, M Ertaş, O Güç, S Hepgüler, S Kiraz,

SZ Oşar, S Öztürk, NS Özyalçın, S Palaoğlu, M Uyar, S Ünal, S Yalçın

International Journal of Medicine and Biomedical Research Vol 2, No 3

(2013)

15. Diffuse amyloid deposition in thyroid gland: a cause for concern in familial Mediterranean

fever. Turhan İyidir Ö, Altay M, Konca Degertekin C, Altınova A, Karakoç A, Ayvaz G, Arslan M,

Öneç K, Arınsoy T, Cesur N, Gönül II.

Amyloid. 2012 Sep;19(3):161-2. doi: 10.3109/13506129.2012.687701. Epub 2012 Jun 5.

16. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes:

experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. Porta M,

Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving

HH, Sjølie AK; DIRECT Study Group.

Diabetologia. 2011 Jun;54(6):1298-303. doi: 10.1007/s00125-010- 2040-1. Epub 2011 Jan 12.

17. Prevalence of peripheral neuropathy and painful peripheral neuropathy in Turkish diabetic

patients. Erbas T, Ertas M, Yucel A, Keskinaslan A, Senocak M; TURNEP Study Group.

J Clin Neurophysiol. 2011 Feb;28(1):51-5. doi: 10.1097/WNP.0b013e3182051334.

18. Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the

association with serum adiponectin, androgen levels, insulin resistance and clinical

parameters. Demirci H, Yilmaz M, Ergun MA, Yurtcu E, Bukan N, Ayvaz G.

Gynecol Endocrinol. 2010 May;26(5):348-55. doi: 10.3109/09513590903367051.

19. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Yilmaz M,

Bukan N, Demirci H, Oztürk C, Kan E, Ayvaz G, Arslan M.

Gynecol Endocrinol. 2009 Apr;25(4):246-52. doi: 10.1080/09513590802653833.

20. Calpain 10 gene single-nucleotide 44 polymorphism may have an influence on clinical and

metabolic features in patients with polycystic ovary syndrome. Yilmaz M, Yurtçu E, Demirci H,

Ergün MA, Ersoy R, Karakoç A, Yetkin I, Cakir N, Ayvaz G, Arslan M.

J Endocrinol Invest. 2009 Jan;32(1):13-7.

21. Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational

diabetes. Rizzo M, Berneis K, Altinova AE, Toruner FB, Akturk M, Ayvaz G, Rini GB, Spinas GA,

Arslan M.

Diabet Med. 2008 Dec;25(12):1406-11. doi: 10.1111/j.1464-5491.2008.02613.x.

22. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes

(DIRECT-Protect 2): a randomised placebo-controlled trial. Sjølie AK, Klein R, Porta M,

Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1385-93. doi: 10.1016/S0140-6736(08)61411- 7. Epub 2008

Sep 25.

23. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1)

of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Chaturvedi N, Porta

M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study

Group.

Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412- 9. Epub 2008

Sep 25.

24. Risk factors for cardiovascular disease in patients with subclinical hypothyroidism. Toruner F,

Altinova AE, Karakoc A, Yetkin I, Ayvaz G, Cakir N, Arslan M.

Adv Ther. 2008 May;25(5):430-7. doi: 10.1007/s12325-008- 0053-7.

25. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on

oral antidiabetic agents: results from the AT.LANTUS trial. Davies M, Lavalle-González F,

Storms F, Gomis R; AT.LANTUS Study Group.

Diabetes Obes Metab. 2008 May;10(5):387-99. doi: 10.1111/j.1463-1326.2008.00873.x. Epub

2008 Mar 18.

26. The association of neurofibromatosis, bilateral pheochromocytoma and primary

hyperparathyroidism. Altinova AE, Toruner F, Cimen AR, Karakoc A, Atasever T, Yetkin I,

Ayvaz G, Cakir N, Arslan M.

Exp Clin Endocrinol Diabetes. 2007 Jul;115(7):468-70.

27. Circulating concentrations of adiponectin and tumor necrosis factor-alpha in gestational

diabetes mellitus. Altinova AE, Toruner F, Bozkurt N, Bukan N, Karakoc A, Yetkin I, Ayvaz G,

Cakir N, Arslan M.

Gynecol Endocrinol. 2007 Mar;23(3):161-5.

28. Serum Ghrelin Levels in patients with Hashimoto's thyroiditis. Altinova AE, Toruner F,

Karakoc A, Yetkin I, Ayvaz G, Cakir N, Arslan M.

Thyroid. 2006 Dec;16(12):1259-64.

29. Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism.

Altinova AE, Törüner FB, Aktürk M, Bukan N, Cakir N, Ayvaz G, Arslan M.

Clin Endocrinol (Oxf). 2006 Oct;65(4):530-5.

30. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels

in obese and lean patients with polycystic ovary syndrome. Yilmaz M, Biri A, Karakoç A,

Törüner F, Bingöl B, Cakir N, Tiras B, Ayvaz G, Arslan M.

J Endocrinol Invest. 2005 Dec;28(11):1003-8.

31. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic

ovary syndrome. Yilmaz M, Karakoç A, Törüner FB, Cakir N, Tiras B, Ayvaz G, Arslan M.

Gynecol Endocrinol. 2005 Sep;21(3):154-60.

32. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in

first-degree relatives of subjects with polycystic ovary syndrome. Yilmaz M, Ergün MA,

Karakoç A, Yurtçu E, Yetkin I, Ayvaz G, Cakir N, Arslan M.

Gynecol Endocrinol. 2005 Oct;21(4):206-10.

33. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in

lean patients with polycystic ovary syndrome. Yilmaz M, Bukan N, Ayvaz G, Karakoç A,

Törüner F, Cakir N, Arslan M.

Hum Reprod. 2005 Dec;20(12):3333-40. Epub 2005 Aug 25.

34. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives

of women with polycystic ovary syndrome. Yilmaz M, Bukan N, Ersoy R, Karakoç A, Yetkin I,

Ayvaz G, Cakir N, Arslan M.

Hum Reprod. 2005 Sep;20(9):2414-20. Epub 2005 May 12.

35. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment. Konuk O, Atasever T,

Unal M, Ayvaz G, Yetkin I, Cakir N, Arslan M, Hasanreisoglu B.

Thyroid. 2005 Apr;15(4):358-63.

36. The effects of hypothyroidism in rats on serum leptin concentrations and leptin mRNA levels

in adipose tissue and relationship with body fat composition. Karakoc A, Ayvaz G, Taneri F,

Toruner F, Yilmaz M, Cakir N, Arslan M.

Endocr Res. 2004 May;30(2):247-55.

37. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese

rats. Törüner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, Aktürk M, Karakoç A, Ayvaz G,

Arslan M.

Horm Metab Res. 2004 Apr;36(4):226-30.

38. Effects of rosiglitazone treatment on the pentose phosphate pathway and glutathione-

dependent enzymes in liver and kidney of rats fed a high-fat diet. Akbay E, Ulusu NN, Töröner

F, Ayvaz G, Taneri F, Aktürk M, Arslan M, Karasu C.

Curr Ther Res Clin Exp. 2004 Jan;65(1):79-89. doi: 10.1016/S0011-393X(04)90007- 0.

39. Effects of diuretics on iodine uptake in non-toxic goitre: comparison with low-iodine diet.

Kapucu LO, Azizoglu F, Ayvaz G, Karakoc A.

Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1270-2. Epub 2003 Jul 3.

40. Insulin secretion and insulin sensitivity in normal pregnancy and gestational diabetes

mellitus. Akbay E, Tiras MB, Yetkin I, Törüner F, Ersoy R, Uysal S, Ayvaz G.

Gynecol Endocrinol. 2003 Apr;17(2):137-42.

41. Acute and chronic effects of different concentrations of free fatty acids on the insulin

secreting function of islets. Ayvaz G, Balos Törüner F, Karakoç A, Yetkin I, Cakir N, Arslan M.

Diabetes Metab. 2002 Dec;28(6 Pt 2):3S7-12; discussion 3S108-12.

42. A comparison of radionuclide thyroid angiography, (99m)Tc-MIBI scintigraphy and power

Doppler ultrasonography in the differential diagnosis of solitary cold thyroid nodules.

Demirel K, Kapucu O, Yücel C, Ozdemir H, Ayvaz G, Taneri F.

Eur J Nucl Med Mol Imaging. 2003 May;30(5):642-50. Epub 2003 Mar 1.

43. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.Konuk O, Atasever T, Unal M,

Ayvaz G, Yetkin I, Cakir N, Arslan M, Hasanreisoglu B.

Thyroid. 2002 Jul;12(7):603-8.

44. Antineutrophil cytoplasmic autoantibody associated vasculitis presenting with hashitoxicosis.

Sancak A, Karakoc A, Yetkin I, Ayvaz G, Cakir N, Aslan M.

Nephron. 2000 Nov;86(3):368-9. No abstract available.

45. Effects of extracellular pH upon the insulinotropic action of alpha-D- glucose pentaacetate.

Ayvaz G, Sener A, Malaisse WJ.

Res Commun Mol Pathol Pharmacol. 1999 Jan;103(1):83-90.

46. A case of Costello syndrome with endocrine features. Yetkin I, Ayvaz G, Arslan M, Yilmaz M,

Cakir N.

Ann Genet. 1998;41(3):157-60.

KİTAP BÖLÜMLERİ

1.“Combined Thyroid-Eye Clinics”. Graves’ Orbitopathy: A Multidiciplinary Approach-Questions and Answers. Fusun Balos Törüner, Onur Konuk, Goksun Ayvaz. Wiersinga WM, Kahaly GJ.(Eds). Basel, Karger 2017, pp: 113-118.

2.”The Patient’s View”. Graves’ Orbitopathy: A Multidiciplinary Approach-Questions and Answers. Georg von Arx, Goksun Ayvaz. Wiersinga WM, Kahaly GJ.(Eds). Basel, Karger 2017, pp: 285-290.

bottom of page